8-氟-1-萘甲醛 | 112641-28-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 8-氟-1-萘甲醛
• 英文名称: 1-formyl-8-fluoronaphthalene
• 英文别名: 8-Fluoro-1-naphthalenecarboxaldehyde；8-Fluoronaphthalene-1-carbaldehyde
• CAS: 112641-28-8
• 化学式: C₁₁H₇FO
• 分子量: 174.174
• InChiKey: WIFMIURQPURGNR-UHFFFAOYSA-N

物化性质

• 沸点：
  303.3±15.0 °C(Predicted)
• 密度：
  1.249±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P330,P363,P501
• 危险性描述：
  H302,H312,H332
• 储存条件：
  2-8℃，惰性气体

反应信息

• 作为反应物：
  描述：

  8-氟-1-萘甲醛 在 草酰氯 、 二甲基亚砜 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 1.5h， 生成 1-Acetyl-8-fluornaphthalin
  参考文献：
  名称：

  4,5-取代的1-乙酰基-8-氟萘在空间中的氢-氟和碳-氟自旋-自旋偶联的合成和实验研究。

  摘要：

  报道了完整的4,5-取代的1-乙酰基-8-氟萘系列化合物的合成和NMR研究（1H，13C和19F）。该数据通过氟和乙酰基上的甲基（1H和13C）之间的空间偶合揭示了6J（H，F）和5J（C，F）。该偶联常数的大小根据C-4处的取代基的性质，核间距离和溶剂而变化。

  DOI：

  10.1016/s1386-1425(99)00215-2
• 作为产物：
  描述：

  1-bromo-8-(t-butyldimethylsilyloxy)methylnaphthalene 在 正丁基锂 、 草酰氯 、 二甲基亚砜 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 25.5h， 生成 8-氟-1-萘甲醛
  参考文献：
  名称：

  4,5-取代的1-乙酰基-8-氟萘在空间中的氢-氟和碳-氟自旋-自旋偶联的合成和实验研究。

  摘要：

  报道了完整的4,5-取代的1-乙酰基-8-氟萘系列化合物的合成和NMR研究（1H，13C和19F）。该数据通过氟和乙酰基上的甲基（1H和13C）之间的空间偶合揭示了6J（H，F）和5J（C，F）。该偶联常数的大小根据C-4处的取代基的性质，核间距离和溶剂而变化。

  DOI：

  10.1016/s1386-1425(99)00215-2

文献信息

• Dihydropyridine derivatives, processes for their preparation and pharmaceutical compositions thereof
  申请人：FISONS plc

  公开号：EP0225175A2

  公开（公告）日：1987-06-10

  There are described compounds of Formula I, in which R₁, R₂, R₃ and R₄ are as defined in the specification, R₅ is alkyl optionally interrupted by an amide group and optionally substituted by halogen or by a carboxy or a heterocyclic group, X is -O-, -NR-, -S(O)m₁, or a bond, Z is hydrogen or together with R forms a bond, R is hydrogen, alkyl or together with Z forms a bond, R₆ is a 5 or 6 membered unsaturated nitrogen containing heterocyclic ring, optionally fused to a phenyl ring and optionally substituted by one or more of oxo, hydroxy, alkyl, -(CH₂)n₁NH₂, alkoxy, phenyl or -COOH, and when X is -NR- or -S(O)m₁-, R₆ may in addition be hydrogen or a group -CH₂CH₂NH₂, -CH₂CH₂-het. or NHC(=NH)NH₂, when X is -O-, R₆ may also be a group -NH₂, -C(=O) (CH₂)nNH₂, -CH₂CH₂NR₁₄R₁₅ or CH₂CH₂OCH₂CH₂NR₁₄R₁₅, when X is -NR-, -S(O)m₁-, or a bond, R₆ may also be hydrogen or a group -C(=NR₁₂)NHR₁₃, R₁₃ and R₁₄ may be hydrogen or alkyl, R₁₂ is hydrogen, alkylcarbonyl, nitrile or hydroxy, R₁₅ is hydrogen or a group R₁₁, m and m₁ are each 0, 1 or 2, n is 0 or 1, n₁ is an integer from 0 to 6 and pharmaceutically acceptable salts, esters, amides, analogues and protected derivatives thereof.

  所述化合物为式 I、 其中 R₁、R₂、R₃ 和 R₄ 如说明书中所定义、 R₅ 是任选被酰胺基打断并任选被卤素或羧基或杂环基取代的烷基、 X 是-O-、-NR-、-S(O)m₁ 或键、 Z 是氢，或与 R 形成键、 R 是氢、烷基或与 Z 共同形成键、 R₆ 是 5 或 6 个成员的不饱和含氮杂环，可选择与苯基环融合，并可选择被氧 化物、羟基、烷基、-(CH₂)n₁NH₂、烷氧基、苯基或-COOH 中的一个或多个取代、 当 X 为-NR-或-S(O)m₁-时，R₆ 还可以是氢或基团-CH₂CH₂NH₂、-CH₂CH₂-热或 NHC(=NH)NH₂ 、 当 X 为 -O- 时，R₆ 也可以是基团 -NH₂、-C(=O) (CH₂)nNH₂, -CH₂CH₂NR₁₄R₁₅ 或 CH₂CH₂OCH₂CH₂NR₁₄R₁₅、 当 X 为-NR-、-S(O)m₁- 或键时，R₆ 也可以是氢或基团-C(=NR₁₂)NHR₁₃、 R₁₃ 和 R₁₄ 可以是氢或烷基、 R₁₂ 是氢、烷基羰基、腈或羟基、 R₁₅ 是氢或基团 R₁₁、 m 和 m₁ 均为 0、1 或 2、 n 为 0 或 1、 n₁ 是 0 至 6 的整数 及其药学上可接受的盐、酯、酰胺、类似物和受保护的衍生物。
• SULFONAMIDE COMPOUND OR SALT THEREOF
  申请人：Taiho Pharmaceutical Co., Ltd.

  公开号：EP3466934A1

  公开（公告）日：2019-04-10

  The present invention provides a novel sulfonamide compound having a ribonucleotide reductase inhibitory activity or a salt thereof, and a pharmaceutical composition containing the same as an active ingredient. A compound represented by Formula (I) [wherein, X1 represents an oxygen atom or the like; X2 represents an oxygen atom; X3 represents -NH-; X4 represents a hydrogen atom or the like; R1 represents -C(R11)(R12)- or the like; R11 and R12 are the same or different and each represents a hydrogen atom or the like; R2 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R3 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R4 represents a hydrogen atom or the like] or a salt thereof.

  本发明提供了一种具有核糖核苷酸还原酶抑制活性的新型磺酰胺化合物或其盐，以及含有该化合物作为活性成分的药物组合物。 由式(I)代表的化合物[其中，X1代表氧原子或类似物；X2代表氧原子；X3代表-NH-；X4代表氢原子或类似物；R1代表-C(R11)(R12)-或类似物；R11和R12相同或不同且各自代表氢原子或类似物；R2代表任选取代的C6-C14芳烃基团或类似物；R3代表任选取代的C6-C14芳烃基团或类似物；R4代表氢原子或类似物]或其盐。
• ANTITUMOR AGENT
  申请人：Taiho Pharmaceutical Co., Ltd.

  公开号：EP3718545A1

  公开（公告）日：2020-10-07

  The present invention provides a method of enhancing an antitumor effect by a compound strongly inhibiting ribonucleotide reductase (RNR) or a salt thereof. A combination formulation involving combined administration of a sulfonamide compound represented by Formula (I) [In the formula, X1 represents an oxygen atom or the like; X2 represents an oxygen atom; X3 represents -NH-; X4 represents a hydrogen atom or the like; R1 represents -C(R11) (R12)- or the like; R11 and R12 are the same or different and each represents a hydrogen atom or the like; R2 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R3 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R4 represents a hydrogen atom or the like] or a salt thereof, having RNR inhibitory activity, and other antitumor agent(s).

  本发明提供了一种通过强抑制核糖核苷酸还原酶（RNR）的化合物或其盐增强抗肿瘤效果的方法。 一种组合制剂涉及联合给药由式(I)代表的磺酰胺化合物[式中，X1代表氧原子或类似物；X2代表氧原子；X3代表-NH-；X4代表氢原子或类似物；R1代表-C(R11)(R12)-或类似物；R11和R12相同或不同，各自代表氢原子或类似物；R2代表任选取代的C6-C14芳烃基团或类似物；R3代表任选取代的C6-C14芳烃基团或类似物；R4代表氢原子或类似物]或其盐，具有RNR抑制活性，以及其他抗肿瘤剂。
• Sulfonamide compound or salt thereof
  申请人：Taiho Pharmaceutical Co., Ltd.

  公开号：US10889555B2

  公开（公告）日：2021-01-12

  The present invention provides a novel sulfonamide compound having a ribonucleotide reductase inhibitory activity or a salt thereof, and a pharmaceutical composition containing the same as an active ingredient. A compound represented by Formula (I) [wherein, X1 represents an oxygen atom or the like; X2 represents an oxygen atom; X3 represents —NH—; X4 represents a hydrogen atom or the like; R1 represents —C(R11)(R12)— or the like; R11 and R12 are the same or different and each represents a hydrogen atom or the like; R2 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R3 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R4 represents a hydrogen atom or the like] or a salt thereof.

  本发明提供了一种具有核糖核苷酸还原酶抑制活性的新型磺酰胺化合物或其盐，以及含有该化合物作为活性成分的药物组合物。 由式(I)代表的化合物[其中，X1代表氧原子或类似物；X2代表氧原子；X3代表-NH-；X4代表氢原子或类似物；R1代表-C(R11)(R12)-或类似物；R11和R12相同或不同且各自代表氢原子或类似物；R2代表任选取代的C6-C14芳烃基团或类似物；R3代表任选取代的C6-C14芳烃基团或类似物；R4代表氢原子或类似物]或其盐。
• An analysis of the complementary stereoselective alkylations of imidazolidinone derivatives toward α-quaternary proline-based amino amides
  作者：Brian J. Knight、Erin E. Stache、Eric M. Ferreira

  DOI：10.1016/j.tet.2015.05.010

  日期：2015.9

  Alkylations of praline-based imidazolidinones are described based on the principle of self-regeneration of stereocenters (SRS), affording high levels of either the cis or trans configured products. Stereoselectivity is dictated solely on the nature of the 'temporary' group, where isobutyraldehyde-derived imidazolidinones provide the cis configured products and 1-naphthaldehyde-derived imidazolidinones afford the complementary trans configured products. These stereodivergent products can be readily cleaved to afford both alpha-alkylated proline enantiomers from readily available L-proline. A series of imidazolidinones were alkylated to investigate the origin of the anti-selectivity. Potential contributions toward the observed anti-selectivity are discussed on the basis of these experiments, suggesting a refined hypothesis for selectivity may be in order. (C) 2015 Elsevier Ltd. All rights reserved.